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ABSTRACT 
Objectives. Systemic sclerosis (SSc) is heterogeneous. The objectives of this 
study were to evaluate the purpose, strengths and limitations of existing SSc 
subset criteria, and identify ideas among experts about subsets.  
Methods. We conducted semi-structured interviews with randomly sampled 
international SSc experts. The interview transcripts underwent an iterative 
process with text deconstructed to single thought units until a saturated 
conceptual framework with coding was achieved and respondent occurrence 
tabulated. Serial cross-referential analyses of clusters were developed. 
Results. Thirty experts from 13 countries were included; 67% were male, 63% 
were from Europe and 37% from North America; median experience of 22.5 
years, with a median of 55 new SSc patients annually. Three thematic clusters 
regarding subsetting were identified: research and communication; management; 
and prognosis (prediction of internal organ involvement, survival). The strength of 
the limited/diffuse system was its ease of use, however 10% stated this system 
had marginal value. Shortcomings of the diffuse/limited classification were the 
risk of misclassification, predictions/generalizations did not always hold true, and 
that the elbow or knee threshold was arbitrary. Eighty-seven percent use more 
than 2 subsets including: SSc sine scleroderma, overlap conditions, antibody-
determined subsets, speed of progression, and age of onset (juvenile, elderly).  
Conclusions. We have synthesized an international view of the construct of SSc 
subsets in the modern era. We found a number of factors underlying the 
construct of SSc subsets. Considerations for the next phase include rate of 
change and hierarchal clustering (e.g. limited/diffuse, then by antibodies).  
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Introduction 
Systemic sclerosis (SSc) is a family of conditions unified by the presence of 
immune activation, systemic vasculopathy and fibrosis. These may result in 
internal organ involvement, variable disease trajectory and survival. Classification 
criteria for subsets of patients with SSc are widely used in clinical research.(1) 
Sixteen clinically based criteria sets have been proposed ranging from 2 to 6 
subsets, usually based on the extent of skin involvement(2-18) The most 
frequently used are those proposed by LeRoy et al in 1988 which classify SSc 
patients as limited or diffuse cutaneous subtypes.(6) Subset classification may be 
used to identify patients with differential disease evolution, response to therapy, 
and prognosis.(7, 11, 19, 20) In a new era of earlier identification of disease(21-
23), autoantibody profiling(24, 25), genetic markers(26), biomarkers(27) and 
personalized medicine(22), the construct of ‘subsets in SSc’ may have evolved.  
 
Development of new subset criteria for SSc is being undertaken, led by the 
international steering committee of American College of Rheumatology (ACR) 
and European League Against Rheumatism (EULAR) classification criteria for 
SSc. An important first step is to evaluate the current construct underpinning the 
meaning and utility of SSc subset criteria. It is also important to understand the 
strengths and limitations of previous iterations of SSc subset criteria so that a 
new iteration of SSc subset criteria will build upon the strengths and address the 
limitations. 
 
The aim of this study is to evaluate the construct of SSc subsets in the modern 
era. Specifically, the objectives of this study are to evaluate the meaning and 
purpose of SSc subset criteria; determine the strengths and limitations of existing 
SSc subset criteria, and identify potential areas for improvement. An accurate 
understanding of the construct underlying SSc subsets will inform the study 
design of the new iteration of SSc subset classification criteria development. 
 
Methods 
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Study design. We conducted a cross-sectional study, with face-to-face 
interviews, to determine the purpose, strengths, limitations and areas of 
improvement for SSc subset criteria. 
 
Sample. Our previous work found that the most valid and reliable beliefs are 
elicited from individuals who have a greater depth of knowledge and 
experience.(28) Thus we interviewed experts in SSc. SSc experts were defined 
as individuals who participate in a referral center for or conduct human research 
in SSc. A list of attendees at the Systemic Sclerosis World Congress (n=771) 
was used to identify SSc experts (those who publish in SSc and/or have a SSc 
program) (n=69). Each SSc expert was assigned a number. SSc experts were 
randomly sampled from the SSc expert list using a computerized random number 
generator. Subjects were contacted using a standardized letter by email inviting 
them to participate in a recorded interview. This recruitment strategy has been 
successfully used in previous work.(29) An interview time was arranged. Each 
participant was assigned a study identification code to maintain anonymity. 
Characteristics of the participants collected included sex, pediatric/adult 
rheumatology/other, years in practice, number of new SSc patients seen per 
year, participation in SSc research, and location of practice. There is no 
consensus on the sample size for a belief elicitation study.(28) Using central limit 
theorem, an a priori sample size of 30 was chosen to assume a normal 
distribution to the mean values of summarized data. This conservative approach 
provides a larger and more robust sample size than usually recommended for 
content analytic studies.(30) Institutional research ethics approval was obtained 
and participants provided written informed consent. 
 
Interview. A 10-minute interview was conducted individually with each expert. 
Using a standardized semi-structured interview template, experts were asked 
open-ended questions investigating their beliefs about the purpose and 
limitations of SSc subset criteria. Appendix 1. The investigator used probes (e.g. 
can you tell me more about that?) to facilitate elaboration of an expert’s 
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comments. The interview was recorded using a dictaphone and transcribed 
verbatim.  
 
Analysis. Participant characteristics were double entered into a computerized 
database and summarized using descriptive statistics. Hsieh and Shannon’s 
qualitative content analytic approach was used to analyze the interview data.(31) 
Independently, 2 investigators (SRJ, MS) read all the transcripts repeatedly to 
achieve immersion and obtain a sense of the whole data set. The transcripts 
were re-read word by word to derive codes by first highlighting the exact words 
from the text that appear to capture key thoughts or concepts. The investigators 
made notes of the initial analysis, and created labels for codes that are reflective 
of the thoughts. The codes were organized into meaningful clusters. The 
incidence of codes and rank order frequency are reported. The results of the 2 
independent analyses were compared. The aggregate results were presented to 
an independent, international group of SSc experts (n=6) for comment and 
identification of conceptual links amongst the themes to develop an analytical 
thematic schema. This research triangulation enhances the credibility of the 
findings and ensures the analysis reflects the full breadth and depth of the 
data.(32) Descriptive statistics were used to summarize the data. Quantitative 
analyses were conducted using RStudio (version 0.97.248). 
 
RESULTS 
SSc experts. Thirty experts from 13 countries were successfully recruited. The 
participants were predominantly male (67%), European (63%) and practiced 
adult rheumatology (87%) with a median of 22.5 (interquartile range 17.3) years 
in practice seeing SSc patients. Two investigators were involved in previous SSc 
subset classification criteria development. Table 1 summarizes participant 
characteristics.  
 
Meaning of SSc subsets. The term SSc subsets meant ‘distinguish patients’ 
into ‘distinct groups’ using terms ‘differentiate’, ‘stratify’, ‘separate’, ‘divide’ and 
Page 9 of 48
Scandinavian Journal of Rheumatology
Scandinavian Journal of Rheumatology
For Peer Review
 9
‘characterized subgroups.’ There was no ambiguity in the meaning of SSc subset 
criteria. 
 
Purpose of SSc subsets. The purpose of SSc subset criteria fell into 3 thematic 
clusters. Under the cluster Management, experts stated that SSc subsets should 
‘guide intensity of investigations at baseline’; ‘intensity of monitoring over time’; 
inform management, treatment/therapeutics, ‘aggressiveness of therapy’ and 
inform ‘response to treatment’. A second thematic cluster Prognosis was 
identified, with 2 sub-clusters: ‘internal organ involvement’ and ‘survival.’ Experts 
stated that SSc subsets should inform prognosis, namely ‘outcomes’, ‘course of 
disease’, ‘changes over time’, ‘disease progression’; ‘function as prognostic 
indicators’ or ‘assist with risk stratification, ideally informing time to organ failure’. 
A third thematic cluster Research and Communication was identified. Experts 
stated that SSc subsets be used ‘during study sample selection to reduce the 
heterogeneity of disease.’ SSc subsets can be used to ‘educate’ patients, 
trainees and medical colleagues about SSc. It facilitates communication among 
health professionals in the patient’s circle of care (see Figure 2). 
 
Strengths of Limited/Diffuse classification system. 100% of experts endorsed 
using the limited/diffuse cutaneous subset system. Experts stated the strengths 
of the limited/diffuse subset system are its ‘ease of use’ and ‘simple to 
understand.’ It ‘has prognostic value,’ ‘informs what to look for,’ ‘useful for 
management’ and ‘applicable for research.’ However, 10% of experts stated that 
this system has little or no value. One expert stated, ‘I put it in the note to 
communicate to other physiciansT. I have more tools and am more 
comprehensive in how we evaluate patient.’ Another expert stated ‘I hate these 
criteria, the skin is the wrong thing.’  
 
The shortcomings of the limited cutaneous and diffuse cutaneous SSc system 
grouped into 4 thematic clusters. Under thematic cluster “Misclassification” 
experts expressed concern relating to the observation that ‘all diffuse starts as 
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limited, and limited can extend to diffuse.’ ‘Everyone starts as limited,’ and this 
system requires ‘expert clinicians and expert centers’ to prevent misclassification. 
A second thematic cluster was ‘predictions or generalizations do not always hold 
true.’ Participants observed that ‘pulmonary arterial hypertension can occur in 
both types,’ and ‘some patients don’t behave the way they are supposed to.’ The 
beliefs that the ‘diffuse type has a worse prognosis,’ ‘anticentromere is 
associated with limited and Scl70 (Topoisomerase1) is associated with diffuse’ 
are not always true. This system is ‘not good enough for predicting organ 
involvement,’ and ‘doesn’t work for lung.’ A third thematic cluster related to the 
use of the elbow as a cutaneous threshold as participants felt that it is an 
‘absolute breakdown without context,’ is ‘arbitrary,’ and that the ‘forearm are 
diffuse in action. A fourth thematic cluster related to dependence on the skin for 
classification. Participants expressed the 2 subset system ‘does not account for 
progression or regression,’ does not reflect the intermediate subtype, and ‘only 
includes observed skin thickening. Participants opined that ‘in early disease the 
skin is not the major organ,’ and ‘skin alone is not useful.’ Other comments 
included ‘limited is not well defined,’ ‘the system does not capture disease 
severity or disease activity,’ ‘is missing antibodies,’ does not account ‘for rate of 
physiologic change,’ and is an ‘oversimplification.’ 
 
Number and types of subsets. Eighty-seven percent of experts use more than 
2 SSc subsets. In practice, the participants endorsed using 2 to 10 subsets. 
Figure 5. SSc sine scleroderma was considered a subset (n=7), whereas others 
explicitly stated SSc sine scleroderma is not a separate subtype (n=2). Overlap 
patients were considered a distinct subset (n=6). Some participants subset SSc 
by autoantibody or antinuclear antibody pattern (n=6), explicitly describing 
centromere, topoisomerase, RNA polymerase, nucleolar pattern and U1RNP 
antibodies. Some participants subset SSc by rate of skin progression (n=3) 
distinguishing ‘rapidly progressive’ from ‘slowly progressive.’ Experts subset SSc 
based on stage of disease, distinguishing ‘early’ versus ‘late’ or ‘established.’ 
Experts also subset based on age of onset distinguishing ‘juvenile onset’ and 
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‘geriatric onset.’ Other described subsets included ‘pre-SSc or undifferentiated,’ 
‘single organ dominant,’ intermediate,’ ‘fibrotic or vasculopathic with or without 
inflammation,’ and considered gene expression and interferon signatures. 
 
DISCUSSION 
We have found that the concept of SSc subsets exists as a multidimensional and 
complex latent construct. It cannot be easily measured but is considered to be 
real by international SSc experts. Ontology is the philosophical study of the 
nature of being, and the categories of being and their relations. Our work 
addresses the ontological questions: ‘what is it?’ and ‘what is it for?’ SSc subset 
criteria have wide ranging utility as they may inform patient care, predict internal 
organ involvement and survival; are needed to identify more homogeneous 
groups of patients for SSc studies and inform medical communication. The 
limited and diffuse cutaneous SSc subset system has been extensively adopted 
over the past 25 years. However, limitations to their use have been identified. 
Our findings suggest there is a need for new systemic sclerosis classification 
criteria. 
 
Our results provide important considerations for the next phase of criteria 
development. Experts continue to be influenced by the degree of skin 
involvement. Skin involvement is a manifestation that is relatively easy to 
measure, is low cost and can be ascertained in any setting. However, an 
emerging concept not included in previous iterations of SSc subset criteria is the 
rate of skin change. Methods of assessing rate of skin change have been 
proposed.(33-35) The next iteration of subset criteria should consider the 
feasibility of incorporating rate of change and its predictive validity for informing 
response to therapy, internal organ involvement and survival. The time from 
disease onset may also affect cutaneous subsetting, and will need to be 
accounted for. 
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The use of autoantibody profiling and nailfold capillaroscopy is increasingly being 
proposed to subset SSc patients.(18, 36) Given their importance, they are now 
items in the American College of Rheumatology European League Against 
Rheumatism classification criteria for systemic sclerosis.(37) The limited and 
diffuse cutaneous system includes centromere and topoisomerase antibodies, 
yet is not always consistent. A wider array of scleroderma-specific antibodies has 
been studied. RNA polymerase3 antibodies have been associated with renal 
crisis. However, the inclusion of a greater number of scleroderma specific 
antibodies in SSc subset criteria will need to tempered against their broad 
availability and cost. Furthermore, there appears to be geographic variation in the 
prevalence of antibodies, notably the prevalence of RNA polymerase III 
antibodies in the US versus southern Europe.(38) The impact of geographic 
variability on the operating characteristics of subset criteria including 
autoantibodies will need to be evaluated. Similarly, the possible role and 
contribution of nailfold capillaroscopic SSc patterns may need to be considered. 
The identification of early, active, and late nailfold capillaroscopic SSc patterns 
may inform subsetting. 
 
The appropriate number of subsets is another important consideration. The 
majority of experts believe there are more than 2 subsets. Previous iterations of 
criteria have proposed up to six subsets. However, a 2 subset system has been 
shown to have the best predictive validity for prognosticating future outcomes in 
SSc.(1) New systems of subset classification will need to consider if the inclusion 
of additional subsets confers incremental value.(17) 
 
Investigators are encouraged to think carefully about how we approach 
development of classification criteria for subsets of disease. Classical 
‘philosophic realism,’ an underpinning of psychometric science, says that the 
notion of subsets within a disease is a real thing that we cannot directly observe 
and therefore called a latent variable or construct.(39) We use combinations of 
symptoms, signs and test results to indicate the construct (i.e. define the 
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subsets). The items that define the construct should be highly correlated and 
interchangeable.(40) The final system of subset classification should be reflective 
of the underlying, real, latent construct. However, it may be that subsets within a 
disease don’t exist as real and independent entities but rather constructed in the 
minds of experts.(40) Under this approach of ‘philosophic constructivism’ the 
items chosen to define subsets form the construct. As a consequence, the use of 
different items to define subsets may result in different outcomes.(40) For 
example, defining subsets by autoantibodies, extent of skin involvement or rate 
of change may differentially predict future organ involvement or survival. 
Researchers have been advised to investigate how constructivism should be 
considered when evaluating the validity of and choosing measures to inform 
patient care or the conduct of research.(40) Combining items of different 
attributes in a hierarchical form (e.g. extent of skin involvement and 
autoantibodies) may address this issue. Figure 6. 
 
One may argue that there may not be 1 subset classification system that serves 
all purposes. Subclassification will create more homogeneous groups, but the 
groups may need to be different based on the intended purpose (to understand 
pathophysiology, prevention or prognosis). The question then, is which is needed 
most by clinicians? Our findings suggest the international expert community 
prefers subset criteria to be associated with future outcomes, namely response to 
therapy and prognosis. For example, experts in this study stated it would be 
‘helpful to identify patients who have a poor prognosis’ and ‘warrant more 
aggressive therapy’, thereby conferring more personalized medicine. Ideally 
subset criteria would help facilitate giving the right drug to the right patient. Once 
subsets are identified, it is important to evaluate predictors of trajectory, and then 
ascertain if these predictors can guide treatment. However, it should be 
remembered that subset classification based on pathophysiology and prognosis 
may not be stable over time as future outcomes can change. 
 
Strengths of this study include interview of a large number of SSc experts, and 
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broad representation of SSc experts from both Europe and North America. We 
have included the perspective of pediatric rheumatology, dermatology and 
gastroenterology, which was a limitation of the 2013 ACR EULAR SSc 
classification criteria.(41) However, since we randomly sampled participants from 
the list of SSc experts attending the Systemic Sclerosis World Congress; and the 
meeting was predominantly attended by SSc experts from Europe and North 
America, no SSc experts currently practicing in Asia, Africa or South America 
were included in this study. In order to develop SSc subset classification criteria 
that are generalizable globally, it is advised to include the perspectives of these 
regions in the subsequent phases of criteria development. 
 
We used research triangulation in data analysis and provided raw data including 
quotations, i.e. indicators of qualitative research of high quality.(32, 42) Moving 
forward, investigators should take into consideration a few cautionary notes. 
First, investigators should be aware of the dangers associated with 
misclassification. Falsely classifying patients may have liability and cost 
consequences.(43) The false positive, false negative rates, positive and negative 
predictive value of the next iteration of subset classification criteria should be 
evaluated and compared against pre-existing subset criteria.(44)  
 
In summary, we have synthesized an international view of the construct of SSc 
subsets in the modern era. A good ‘photograph’ of the present situation has been 
achieved. We found there are a number of factors underlying the construct of 
SSc subsets including disease trajectory, prediction of internal organ 
involvement, response to therapy, prognosis including survival. Data improving 
our understanding of the relevant domains and their relative importance will 
inform the study design of the next phase of SSc subset criteria development.  
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Table 1. Summary of participant characteristics 
 
Characteristics 
 
n=30 
 
Male sex n (%) 20 (67%) 
Geographic region  
   Europe n (%) 19 (63%) 
      Sweden  1 
      United Kingdom  4 
      Italy  2 
      Germany  5 
      France  1 
      Netherlands  1 
      Switzerland  1 
      Hungary  1 
      Serbia  1 
      Spain  1 
      Poland  1 
   North America n (%) 11 (37%) 
      Canada  1 
      United States of America  10 
Specialty  
   Adult rheumatology n (%) 26 (87%) 
   Pediatric rheumatology n (%)  1 (3%) 
   Adult and pediatric rheumatology n (%) 1 (3%) 
   Dermatology n (%) 1 (3%) 
   Gastroenterology n (%) 1 (3%) 
Number of years in practice seeing SSc patients median 
(IQR) 
22.5 (17.3) 
Number of new SSc patients seen per year median (IQR) 55 (120) 
Conduct of SSc research n (%) 30 (100%) 
Use of SSc subset criteria n (%) 30 (100%) 
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Figure 1. Circle graph illustrating the thematic clusters ‘Management’ for the 
purpose of systemic sclerosis subset criteria.  
 
Figure 2. Circle graph illustrating the thematic cluster ‘Prognosis’ for the purpose 
of systemic sclerosis subset criteria.  
 
Figure 3. Circle graph illustrating the thematic cluster ‘Types of outcomes’ for the 
purpose of systemic sclerosis subset criteria.  
 
Figure 4. Circle graph illustrating the thematic cluster “Research and 
Communication’ for the purpose of systemic sclerosis subset criteria.  
 
 
Figure 5. Number of subsets 
 
 
Figure 6. Illustrative example of hierarchical clustering for systemic sclerosis 
subsets 
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